Syd Johnson mainly focuses on Antibody, Virology, Monoclonal antibody, Epitope and Virus. The Antibody study combines topics in areas such as Cell biology and Effector. The concepts of his Virology study are interwoven with issues in Bacterial vaccine, Immune system and Microbiology.
His study focuses on the intersection of Monoclonal antibody and fields such as Dengue virus with connections in the field of Immunity and Immunization. His primary area of study in Epitope is in the field of Epitope mapping. His Epitope mapping research integrates issues from West Nile Virus Vaccines, Viral envelope and Flavivirus.
His main research concerns Antibody, Monoclonal antibody, Virology, Immunology and Cancer research. He has included themes like B-cell lymphoma and Effector in his Antibody study. His research in Monoclonal antibody intersects with topics in Receptor, Fc receptor, Molecular biology, Avidity and Epitope.
His Virology study frequently draws connections between related disciplines such as Epitope mapping. His Epitope mapping research includes elements of West Nile Virus Vaccines and Viral envelope. His work carried out in the field of Cancer research brings together such families of science as Cancer cell, Cancer, Cytotoxic T cell and Antigen.
His scientific interests lie mostly in Cancer research, Chemistry, Antigen, Monoclonal antibody and Pharmacology. His Cancer research study integrates concerns from other disciplines, such as Cancer, Colorectal cancer, Immunotherapy, CD8 and Cytotoxic T cell. His Monoclonal antibody study improves the overall literature in Antibody.
Syd Johnson regularly ties together related areas like Immune system in his Antibody studies. His Pharmacology research is multidisciplinary, relying on both CD3, Cytokine and CD19. His Receptor research incorporates themes from Chikungunya, Virus, Virology and Transgene.
His primary areas of study are Cancer research, Immune system, CD3, CD19 and Granzyme. His work is dedicated to discovering how Cancer research, CD8 are connected with Cancer and other disciplines. His Immune system research is multidisciplinary, incorporating perspectives in Transgene, Chikungunya, Virus, Virology and Receptor.
His research integrates issues of Perforin, Peripheral blood mononuclear cell, Refractory and Pharmacology in his study of CD3. In his study, Leukemia is inextricably linked to B cell, which falls within the broad field of CD19. His Granzyme study is concerned with the larger field of Antigen.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus
Syd Johnson;Cynthia Oliver;Gregory A. Prince;Val G. Hemming.
The Journal of Infectious Diseases (1997)
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus
Theodore Oliphant;Michael Engle;Grant E Nybakken;Chris Doane.
Nature Medicine (2005)
Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection
Theresa M. Wizemann;Jon H. Heinrichs;John E. Adamou;Alice L. Erwin.
Infection and Immunity (2001)
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
Herren Wu;David S. Pfarr;Syd Johnson;Yambasu A. Brewah.
Journal of Molecular Biology (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors
Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin.
Cancer Research (2007)
Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification
Scott J. Balsitis;Katherine L. Williams;Ruben Lachica;Diana Flores.
PLOS Pathogens (2010)
Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain.
The Lancet (2011)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke.
Structural basis of West Nile virus neutralization by a therapeutic antibody
Grant E. Nybakken;Theodore Oliphant;Syd Johnson;Stephen Burke.
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.
John E. Adamou;Jon H. Heinrichs;Alice L. Erwin;William Walsh.
Infection and Immunity (2001)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: